JBC Anatrace, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M206801200 on August 6, 2002

J. Biol. Chem., Vol. 277, Issue 43, 40989-40996, October 25, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/43/40989    most recent
M206801200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, L.
Right arrow Articles by Javitch, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, L.
Right arrow Articles by Javitch, J. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

beta 2 Adrenergic Receptor Activation

MODULATION OF THE PROLINE KINK IN TRANSMEMBRANE 6 BY A ROTAMER TOGGLE SWITCH*

Lei ShiDagger §, George Liapakis||, Rui Xu§, Frank Guarnieri**, Juan A. BallesterosDagger Dagger , and Jonathan A. JavitchDagger §§§¶¶

From the Dagger  Center for Molecular Recognition, Departments of § Pharmacology and §§ Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York 10032, the ** Sarnoff Corporation, Princeton, New Jersey 08543, Dagger Dagger  Novasite Pharmaceuticals Inc., San Diego, California 92121, and the || Department of Pharmacology, University of Crete School of Medicine, Heraklion 71110, Greece

Received for publication, July 8, 2002, and in revised form, August 2, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In many rhodopsin-like G-protein-coupled receptors, agonist binding to a cluster of aromatic residues in TM6 may promote receptor activation by altering the configuration of the TM6 Pro-kink and by the subsequent movement of the cytoplasmic end of TM6 away from TM3. We hypothesized that the highly conserved Cys6.47, in the vicinity of the conserved Pro6.50, modulates the configuration of the aromatic cluster and the TM6 Pro-kink through specific interactions in its different rotamer configurations. In the beta 2 adrenergic receptor, mutation of Cys6.47 to Thr, which in an alpha -helix has a different rotamer distribution from Cys and Ser, produced a constitutively active receptor, whereas the Ser mutant was similar to wild-type receptor. Use of the biased Monte Carlo technique of Conformational Memories showed that the rotamer changes among Cys/Ser/Thr6.47, Trp6.48, and Phe6.52 are highly correlated, representing a rotamer "toggle switch" that may modulate the TM6 Pro-kink. Differential modulation of the accessibility of Cys6.47 and an engineered Cys6.52 in wild type and a constitutively active background provides experimental support for the association of this rotamer switch with receptor activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

G-protein-coupled receptors (GPCRs)1 are comprised of an extracellular N terminus, seven transmembrane alpha -helical segments (TMs) connected by intracellular and extracellular loops, and a cytoplasmic C terminus. In the beta 2 adrenergic receptor (beta 2AR) and related rhodopsin-like GPCRs that bind small molecules, the binding site is formed among their seven TMs in a water-accessible binding site crevice (1). The transmembrane domain of these receptors, therefore, transduces the binding of ligands, such as biogenic amines, to the activation of intracellular G-proteins, which in turn mediate downstream signal transduction pathways. Even in peptide and glycoprotein hormone receptors, in which the binding site is formed, at least in part, by extracellular loops or by large N-terminal domains, respectively, agonist binding must still be transduced via the transmembrane segments to the intracellular G-protein-interacting regions of these receptors.

Understanding the function of GPCRs at a molecular level requires an understanding of how agonist binding to the receptor is converted into receptor activation (2). Studies based on electron paramagnetic resonance spectroscopy, fluorescence spectroscopy, alterations in cysteine accessibility, and engineering of metal-binding sites have altogether pointed to a key role for conformational changes of TM3 and TM6 in receptor activation (3-8). It has been suggested that protonation of the Asp in the highly conserved (D/E)RY motif at the cytoplasmic side of TM3 leads to release of constraining intramolecular interactions, thereby resulting in movements of TM3 and TM6 and conversion of the receptor to the active state. This hypothesis has been supported by the observation that charge-neutralizing mutations of the Asp/Glu3.49 in TM3 lead to increased agonist-independent activation of a number of GPCRs (7, 9-12).

Experiments using cysteine cross-linking and engineered metal ion-binding sites (3, 4, 13) suggest that residues at the cytoplasmic ends of TM3 and TM6 face each other. We proposed that in the inactive state Arg3.50, in addition to interacting with Asp3.49, also interacts with the conserved Glu6.30 at the cytoplasmic end of TM6, and that this interaction contributes to maintaining the receptor in the inactive state by holding together the cytoplasmic ends of TM3 and TM6. Our experimental data (14) together with the high-resolution structure of rhodopsin (15) suggest that ionic interactions between Asp/Glu3.49, Arg3.50, and Glu6.30 may constitute a common switch governing the activation of many rhodopsin-like receptors. Disruption of the interaction between TM3 and TM6 produces constitutive receptor activation and the extent of constitutive activation is highly correlated with the extent of conformational rearrangement in TM6 (14).

Experimental and computational simulation studies indicate that conformational switches in transmembrane alpha -helices can be generated via Pro-containing motifs that form flexible molecular hinges (16). Although Farrens et al. (3) predicted that a rigid body motion of TM6 relative to TM3 was associated with the activation of rhodopsin, the movements crucial to activation may involve flexibility about the hinge formed by the highly conserved Pro in TM6 (Pro-2886.50 in beta 2AR) (17). In rhodopsin, and presumably in the beta 2AR, TM6 exists in a highly bent configuration, with its cytoplasmic end near to the cytoplasmic end of TM3 (15).

In the beta 2AR and related aminergic receptors, a cluster of highly conserved aromatic residues surrounding the Pro-kink, including Phe6.44, Trp6.48, Phe6.51, and Phe6.52 in catecholamine receptors, face the binding-site crevice (reviewed in Ref. 1). Binding of agonist to a residue or residues in this "aromatic cluster" has been hypothesized to induce or stabilize an altered configuration of the side chains within this cluster that promotes receptor activation (17). Such a conformational rearrangement of the aromatic cluster may be associated with an alteration in the configuration of the TM6 Pro-kink and the subsequent movement of the cytoplasmic end of TM6 away from TM3.

In the beta 2AR the conserved endogenous Cys-2856.47, positioned i-3 from the conserved Pro-2886.50, becomes accessible to methanethiosulfonate ethylammonium (MTSEA) in the binding-site crevice in constitutively active mutants (CAMs) (6, 7, 14). Cys, Ser, and Thr can hydrogen bond (H-bond) to the backbone in an alpha -helix, and this interaction may impact significantly not only the local conformation but may also lead to long range conformational changes through bends and distortions generated in the helix backbone (18-20). The highly conserved Cys-2856.47 near the Pro-kink at 6.50 can H-bond to different backbone carbonyls in different rotamer positions, and its rotamer position may modulate the TM6 kink.

We hypothesized that the configuration of the TM6 Pro-kink in a GPCR would be correlated with constitutive activity and that both Cys6.47 and the aromatic cluster may impact this configuration. We tested these hypotheses in the beta 2AR by assessing the binding and activation properties of Cys6.47 mutants. The biased Monte Carlo technique of Conformational Memories was used to probe for correlations between the Cys-2856.47 rotamer position, the configuration of the aromatic cluster in TM6, and the TM6 Pro-kink conformation. We carried out cysteine accessibility experiments to test a prediction that arose from the simulations, and the experimental results supported the existence of a critical rotamer "toggle switch" (17) associated with receptor activation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Numbering of Residue and Residue Index

Residues are numbered according to their positions in the human beta 2AR sequence. We also index residues relative to the most conserved residue in the TM in which it is located (21). By definition, the most conserved residue is assigned the position index "50," e.g. Pro-2886.50 and therefore Leu-2876.49 and Phe-2896.51. This indexing simplifies the identification of aligned residues in different GPCRs. Mutants are named as WT residue, residue number, superscript index number, and mutant residue where the residues are given in single letter codes.

Nomenclature of chi 1 Rotamer

Different nomenclatures have been used to describe the rotamers of side chain torsion angles. When the heavy atom at the gamma  position is at a position opposite to the backbone nitrogen, when viewed from beta -carbon to alpha -carbon, we define the chi 1 rotamer as in the trans (t) position; from the same viewing angle, when the heavy atom at the gamma  position is at a position opposite to the backbone carbon, we define the chi 1 rotamer as in the gauche+ (g+) position; when the gamma -carbon is opposite to the alpha -hydrogen, we define the chi 1 rotamer as in the gauche- (g-) position.

beta 2-Plasmids and Site-directed Mutagenesis

The mutations were generated by the polymerase chain reaction-mediated mutagenesis using Pfu polymerase (Stratagene). The polymerase chain reaction-generated DNA fragments containing the mutations were subcloned into the appropriate plasmid. The mutations were identified initially through the presence of diagnostic restriction sites introduced via the mutated oligonucleotides and subsequently verified by DNA sequencing analysis of the polymerase chain reaction-generated segments. For stable expression in HEK 293 cells, this cDNA was subcloned into the bicistronic expression vector pCIN4-SFbeta 2AR6His (22).

Cell Culture and Transfection

HEK 293 cells were maintained at 37 °C in 5% CO2 in Dulbecco's modified Eagle's medium/F-12 (1:1) containing 3.15 g/liter of glucose in 10% bovine calf serum. The HEK 293 cells were transfected with 2 µg of the pCIN4 constructs using the LipofectAMINE/Opti-MEM (Invitrogen) transfection system, and a stably transfected pool was selected with Geneticin (700 µg/ml) (6).

Membrane Preparation and [3H]CGP-12177 Binding

To increase the expression of the constitutively active mutant, a 10 µM concentration of the inverse agonist sotalol was added to the growth medium of HEK 293 cells stably expressing WT or mutant beta 2AR for 1-2 days. Membranes were prepared as described previously (14). Aliquots of diluted membrane suspension (200 µl) were incubated in binding buffer either with six different concentrations of the antagonist [3H]CGP-12177 between 40 and 1100 pM (in saturation binding experiments) or with increasing concentrations of agonists or antagonists in the presence of 100 pM [3H]CGP-12177 (in competition binding experiments). The total volume was adjusted to 1.0 ml, and the binding experiments and data analysis were performed as described previously (22, 23).

cAMP Accumulation Assay

HEK 293 cells stably expressing the WT beta 2AR or the mutants were plated in 96-well cell culture plates (pretreated with poly-L-lysine, 0.1 mg/ml) at a density of 40,000-60,000 cells/well. After incubation overnight at 37 °C in 5% CO2, the cells were 95-100% confluent. The medium was removed, and 100 µl of 0-60 µM N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) in Opti-MEM (Invitrogen) was added to normalize the concentration of receptor (22). The concentration of EEDQ used for a particular experiment was adjusted based on the level of cell surface expression of the particular mutant, as higher expressing receptors such as WT required higher concentrations of EEDQ for appropriate normalization. The level of cell surface expression of WT and the mutants was determined by specific binding of the hydrophilic radioligand [3H]CGP-12177 at a concentration 10-fold higher than its KD (0.9 nM). cAMP accumulation assay was performed as described previously (22).

Reactions of F2906.52C Mutants with MTS Reagents

Whole cells from a 35-mm dish were resuspended in 400 µl of buffer A. Aliquots (50 µl) of cell suspension were incubated with freshly prepared MTSEA (Toronto Research Biochemicals) at the stated concentrations at room temperature for 2 min. Cell suspensions were then diluted 20-fold, and 300-µl aliquots were used to assay for [3H]CGP-12177 (1.2 nM) binding in triplicate as described above. The fractional inhibition was calculated as 1-[(specific binding after MTS reagent)/(specific binding without reagent)].

Rotamer Statistics of Cys/Ser/Thr of Membrane Proteins

The distributions of the chi 1 rotamer of Cys/Ser/Thr were calculated from all the high resolution (<= 3 Å) membrane protein structures currently available. The structures were downloaded from the Protein Data Bank. The list and definitions of transmembrane alpha -helical segments were updated and modified using the Membrane Protein Topology data base (24). Cys/Ser/Thr in transmembrane alpha -helical segments were only included if at least 5 residues N-terminal to the identified position were within the alpha -helix. Only regions with a B-value <= 40 (25) and structures with a resolution <= 3 Å were included in the analysis. Our rationale was that a resolution <= 3 Å can differentiate whether or not a region is alpha -helical and B-values <= 40 of the Cys/Ser/Thr side chain atoms ensure that coordinate information was reliable.

Conformational Memories

The approach of Conformational Memories, which is a two-phase biased Monte Carlo simulation, was described previously (26). We used this algorithm, which was implemented in CHARMM (27), to probe the conformational space of TM6 of human beta 2AR.

Initial Structures-- The template was TM6 (6.40-6.56) of chain A of the bovine rhodopsin structure (Protein Data Bank number 1HZX). The side chains of the residues were mutated to those of the aligned positions in the human beta 2AR. Four Ala residues in a standard alpha -helical conformation were added at the N and C termini. Thus, there are totally 25 residues in the system. The alpha -helix was capped by acetamide at the N terminus and N-methylamide at the C terminus. chi 1 of 6.47 (Cys/Ser/Thr) was manually placed in gauche+ (g+), gauche- (g-), or trans (t). chi 1 of 6.48 and 6.52 were manually placed in g+ or t, and in g+/g+, g+/t, and t/t combinations (see "Results"). The initial structures were energy minimized by CHARMM (27b1). During the minimization, the backbone atoms were harmonically constrained with a force constant of 10, and the chi 1 of the 6.47, 6.48, and 6.52 side chains were constrained by well shaped energy barriers around a specific rotamer.

Biased (Constrained) Exploring Phase-- In the initial conformational memories, the backbone angles (phi and psi ) of 6.44-6.52 were distributed with ±50° freedom from the rhodopsin structure values (10% in each of the designated 10° buckets); those of 6.40-6.43 and 6.53-6.56 were distributed within ±25° freedom (20% at each of designated 10° buckets). The dihedral angles of the alanines in the N and C termini were set to those of a standard alpha -helix (phi = -65° psi  = -40°). Side chain torsion angles were able to freely rotate except for the chi 1 of 6.47. The chi 1 of 6.47 (Cys/Ser/Thr) was constrained to g+, g-, or t as specified under "Results."

Forty runs of Monte Carlo simulated annealing were carried out within the above defined conformational memories, with a distance dependent dielectric with a coefficient of 2. Each run of Monte Carlo simulated annealing consisted of a walk from 2070 to 310 K in 18 temperature intervals with a cooling schedule of Tn+1 = 0.9 Tn, and 25,000 steps per temperature. At each step, 2 dihedral angles were randomly selected to change within the allowed conformational memories, and the trial conformation was accepted or rejected according to the standard Metropolis criteria with a Boltzmann probability function defined at the given temperature.

Biased Sampling Phase-- Several hundred structures were collected for each combination of chi 1 of 6.47, 6.48, and 6.52 (see "Results"), based on the biased conformational memories created by the biased (constrained) exploration phase. Each structure was generated after a run of biased Monte Carlo simulated annealing. Each run in this phase consisted of a walk of 15,000 steps at 310 K. At each step, 2 dihedral angles were randomly selected to change within the output conformational memories from the biased exploring phase. Difference structures were generated by changing the odd random number seed.

Analysis of the Output Simulation Structures

The resulting simulation structures were first classified according to their chi 1 rotamer positions of 6.48 and 6.52 (see "Results"). For each structure in each group, the corresponding coordinates were extracted to calculate the following parameters: the phi and psi  of 6.44-6.52 and their individual averages for each group; the population distribution of chi 1 of 6.44, 6.47, 6.48, 6.51, and 6.52; the distances between the atoms at the gamma  position of Cys/Ser/Thr (6.47) to the carboxyl oxygen at i-3 (6.44) and i-4 (6.43) and the average for each group.

The Pro-kink can be described with bend angle, wobble angle, and face shift (28). To assess the configuration across the Pro-kink rather than only the configuration N-terminal to the Pro, we have defined the face shift differently from Visiers et al. (28). We used the angle between the projection of the average of the vectors connecting the alpha -carbons of the (i-3) and (i-4) amino acids with the origin in the y,z-plane (A-34) and the projection of the average of the vectors connecting the alpha -carbons of the (i+3) and (i+4) amino acids with the origin in the y,z-plane, instead of the angle between A-34 and the projection of the vector connecting the proline alpha -carbon with origin in the y,z-plane in Ref. 28. The transformation of the coordinates was similar to Visiers et al. (28). The calculation was implemented in a Perl script that automatically calls CHARMM to calculate the helix axis and extract the results from the output.

The output simulation structures were clustered using Macromodel/Xcluster. Representative structures and the largest clusters were selected for illustration and these were superimposed on the backbone atoms of 6.49 to 6.60 (extracellular region).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Potential Conformations and Backbone Interactions of Cys6.47-- Cysteine residues in an alpha -helical context are restricted to the gauche+ (g+) and trans (t) rotamer conformations (Table I), because the gauche- (g-) configuration induces a steric clash between the sulfur atom and the backbone carbonyl of the i-3 position (20). The rotamer distribution of these side chains in an alpha -helical context is quite similar in soluble and membrane proteins (Table I) and is consistent with the theoretical free energy calculated for different rotamers (29).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Rotamer statistics of Cys/Ser/Thr within an alpha -helical context

In the g+ rotamer, Cys6.47 can H-bond the backbone carbonyl of the i-4 residue, and this is the most common rotamer configuration for a Cys residue in an alpha -helix. In an alpha -helix, the cyclic side chain of proline prevents its H-bonding to the i-4 backbone carbonyl and also induces steric clash, thereby bending the helix. The resulting Pro-kink conformation also prevents H-bonding of the i+1 backbone amide to the i-3 backbone carbonyl (16, 30). Cys6.47 is i-3 from Pro6.50, and in the t rotamer, the backbone carbonyl of 6.47 can act as an H-bond acceptor for its own side chain. Thus, Cys6.47 can adopt two different rotamers, and each rotamer can interact with the TM6 backbone differently, with the potential to induce different conformations of the adjacent Pro-kink. Unlike Cys and Ser, which can populate the t rotamer, the beta -branched Thr does not exist in t, because of steric clash between the side chain methyl and the backbone carbonyls at i-3 and i-4. We therefore mutated Cys-2856.47 to Thr to assess the effect of eliminating the t rotamer at this position, and to Ser as a control.

Pharmacological Characterization of Mutant Receptors-- The affinity of the antagonist [3H]CGP-12177 was not significantly different in the mutants (C2856.47T and C2856.47S) and WT (Table II). C2856.47T had a 5-fold higher affinity for the agonist isoproterenol than did WT, whereas the affinity of C2856.47S was reduced 2-fold (Table II). In intact cells, the maximum level of [3H]CGP-12177 binding to C2856.47T was ~20% that of WT, whereas that of C2856.47S was ~50% of WT (data not shown). After normalization of receptor number with the alkylating reagent EEDQ, the mean and standard error values for the EC50 of the agonist epinephrine in the accumulation of cAMP were 6.0 ± 1.2 (n = 3), 9.4 ± 1.2 (n = 3), and 1.6 ± 0.43 nM (n = 3) for WT, C2856.47S, and C2856.47T, respectively (Fig. 1). Thus, the potency of epinephrine was increased ~4-fold in C2856.47T. A higher potency for agonist activation and increased agonist affinity in competition experiments are features commonly associated with CAMs (31).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Antagonist and agonist binding to WT beta 2AR and the mutants
Saturation and competition binding to membranes prepared from WT and the mutants were performed as described under "Experimental Procedures."


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Epinephrine dose-response curves of WT and mutants. cAMP accumulation in the WT and mutant receptors was measured at the indicated epinephrine concentrations. Based on a determination of [3H]CGP-12177 binding, the concentrations of the alkylating reagent EEDQ (60 µM for WT and 13 µM for C2856.47S) equalized the number of receptors on the cell surface in WT and C2856.47S to that of C2856.47T. Nonlinear regression was carried out using the mean normalized values of three experiments. EC50 values were obtained by fitting the data to a one-site sigmoidal model. The EC50 values were 6.0, 9.4, and 1.6 nM for WT, C2856.47S, and C2856.47T, respectively.

The Increased Basal cAMP Accumulation of C2856.47T Can Be Reduced by Inverse Agonist-- We measured cAMP accumulation after attempting to equalize the number of receptors by inactivating WT and C2856.47S by pretreatment with EEDQ. Under these conditions, basal cAMP accumulation in C2856.47T was about 2-fold higher than in WT and 6-fold higher than in C2856.47S (Fig. 2A). In the presence of an appropriate concentration of forskolin, which directly activates adenylate cyclase, we still observe an effect of receptor activation on cAMP accumulation because of the synergistic effects of forskolin and Galpha s on adenylate cyclase. The increase in cAMP produced by forskolin, however, raises "basal" levels to a level where our assay is more sensitive. Therefore, we also examined the effects of the mutations of 6.47 on cAMP accumulation in the presence of 10 µM forskolin. In the presence of forskolin the 2-fold elevation in cAMP in C2856.47T relative to WT and 6-fold relative to C2856.47S was also observed (Fig. 2B), consistent with the basal determinations reported above. Most importantly, treatment with the inverse agonist timolol (1 µM) did not significantly affect cAMP accumulation in WT or C2856.47S (Fig. 2).2 In contrast, the cAMP accumulation in C2856.47T was significantly decreased to a level similar to that of WT and C2856.47S in both the basal and the forskolin background (Fig. 2).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Basal cAMP accumulation in the WT and mutant receptors. The cAMP accumulation was measured with (open bars) or without (filled bars) the inverse agonist timolol (1 µM). Panel A shows basal cAMP values. Panel B shows basal cAMP values measured in the presence of 10 µM forskolin. Mean ± S.E. are shown (n = 3-4). Based on a determination of [3H]CGP12177 binding, the concentrations of the alkylating reagent EEDQ (35 µM for WT and 13 µM for C285S) equalized the number of receptors in C2856.47S to that of C2856.47T, but the number of WT receptors was only reduced to twice that of the other mutants (data not shown).

Correlation between the chi 1 Rotamers of Cys6.47, Trp6.48, and Phe6.52-- The side chain conformations of Trp and Phe residues in an alpha -helical environment are restricted to g+ or t conformations, given that the g- rotamer gives rise to steric clashes with the helix backbone (20). In the simulations, when Trp6.48 adopted the t rotamer, Phe6.52 also adopted the t rotamer, whereas when Trp6.48 adopted the g+ rotamer, Phe6.52 was found in both conformations. On the other hand, when Phe6.52 adopted the g+ rotamer, Trp6.48 also adopted the g+ rotamer, whereas when Phe6.52 adopted the t rotamer, Trp6.48 was found in both conformations. This pattern most likely results from a steric clash between Trp6.48 in t and Phe6.52 in g+ (Fig. 3A), which is dependent upon their positioning within the Pro-kink. In contrast, this combination of rotamer conformations is tolerated without clash in a standard alpha -helix in a number of known proteins (data not shown). The clash between Trp6.48t and Phe6.52g+ implies the following correlated motions: if Trp6.48t right-arrow Phe6.52t and if Phe6.52g+ right-arrow Trp6.48g+. Thus, as proposed by Visiers et al. (17), these two aromatic residues act as a toggle switch.


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 3.   Three-dimensional molecular representations of the rotamer toggle switch. A, a three-dimensional molecular representation of the effect of local rotamer conformation on the Pro-kink configuration. The representative structures of Cys6.47t/Trp6.48g+/Phe6.52g+ (green) and Cys6.47g+/Trp6.48t/Phe6.52t (red) were taken from the Conformational Memories simulations. 200-300 structures from each cluster were superimposed on the backbone of 6.49-6.60, and their backbone ribbons are shown. Side chains of 6.47, 6.48, 6.50, and 6.52 are shown in stick representation. B, left panel shows the interaction the side chain of Cys6.47 in the t rotamer with Trp6.48 in g+, representing the putative inactive state, which lowers the reactivity of Cys6.47 with MTSEA (see text). Right panel shows the side chain of Cys6.47 in the g+ rotamer and Trp6.48 in t, representing the putative active state, with increased accessibility and reactivity of Cys6.47. C, left panel shows the lack of interaction between Trp6.48 in g+ with a substituted Cys at 6.52 in the putative inactive state. Right panel shows the interaction between Trp6.48 in t and a substituted Cys at 6.52 in the putative active state, thereby decreasing the accessibility and reactivity of Cys6.52 (see text). The Cys6.47 sulfur is shown in yellow.

In our initial conformational searches, we found that particular starting conformation/rotamer positions significantly impacted upon the final distribution of distinct conformations. For example, if we started the conformational search from Trp6.48t/Phe6.52t, >90% of the resulting structures contain Trp6.48t/Phe6.52t (data not shown). This likely resulted from the favorable interaction between the aromatic side chains, the propensity for aromatic residues to be in t in alpha -helices (32), and the need for complex coordinated changes of multiple side chains and/or backbone angles for movement of these side chains. In contrast, if the search started from Trp6.48g+/Phe6.52 g+, the position of these two side chains in the resulting structures was highly correlated, with either g+/g+ (59 and 79%) or t/t (34 and 9%), depending on the rotamer at 6.47 (g+ or t, respectively; see below).

In an attempt to minimize the impact of the starting structure, we started simulations with Trp6.48 in g+ and Phe6.52 in t, thereby breaking the correlation between the rotamers at these two positions. If we started from Trp6.48g+/Phe6.52t, a high percentage of the resulting structures leave the starting uncorrelated state and become correlated, either in t/t or g+/g+ (Table III). We analyzed the relationship in the final structures between the 6.47 rotamer and the different rotamer combinations of 6.48 and 6.52 (Table III). There was a clear correlation between the rotamer position of Cys6.47 and the resulting rotamer conformation of 6.48. Specifically, when Cys6.47 was in g+, 73% of 6.48 moved from the initial g+ to t. In contrast, when 6.47 was in t, 87% of 6.48 remained in g+ (Table III). Similarly, with Thr6.47 in g+ or g-, 73 and 67% of 6.48, respectively, moved from the initial g+ to t. With Ser6.47 in g+ or g-, 61 and 68% of 6.48, respectively, moved from the initial g+ to t, whereas with Ser6.47 in t, 70% of 6.48 remained in g+. Because Thr does not exist in t, it is likely, therefore, that in the C2856.47T mutant the Trp6.48 is significantly overrepresented in t compared with its rotamer distribution with Cys or Ser at 6.47. 

                              
View this table:
[in this window]
[in a new window]
 
Table III
The correlation of chi 1 of Cys6.47, Trp6.48, and Phe6.52
The ratios of different combination of rotamers of resulting structures from the conformational search are shown according to the ending rotamer of 6.48 and 6.52. The starting combination of chi 1 6.48/6.52 was g+/t (see text). The chi 1 of 6.47 was restrained at g+, g-, or t, as indicated.

Modulation of the Pro-kink in TM6 by the chi 1 Rotamer of 6.47, 6.48, and 6.52-- The resulting simulation structures can be clustered into two major groups based on the rotamer conformations of 6.47, 6.48, and 6.52, one with Cys6.47t/Trp6.48g+/Phe6.52g+ and the other with Cys6.47g+/Trp6.48t/Phe6.52t. These two clusters have significant differences in the parameters representing the global characteristics of the Pro-kink, which results primarily from the significant alteration in the backbone torsion angles of 6.47 and 6.48 (Table IV). Even a small local change in backbone resulting from the different rotamer combinations could have a large impact on the position of the cytoplasmic end of TM6.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Structural effects of different rotamer combinations of 6.47, 6.48, and 6.52 
The values are the means from the ~200 representative structures of Cys6.47 t/Trp6.48 g+/Phe6.52 g+ and Cys6.47 g+/Trp6.48 t/Phe6.52 t shown in Fig. 3A.

Thr at 6.47 exists predominantly in the g+ rotamer, and it does not exist in the t rotamer. Because the Thr6.47 mutant shows an activated phenotype, the 6.47 g+ conformation seems to favor and/or mimic the active state. In contrast, Ser, which can populate the t rotamer, showed a distribution of states similar to that of WT. Thus, we hypothesize that Cys6.47t/Trp6.48g+/Phe6.52g+ represents the inactive conformation of the receptor and that Cys6.47g+/Trp6.48t/Phe6.52t represents the active state (see "Discussion").

MTSEA Reaction Rate of F2906.52C in WT and CAM Background-- Cys-2856.47 in beta 2AR is responsible for the inhibitory effect of MTSEA on ligand binding in several beta 2AR CAMs (6, 7, 14). We inferred that this increased accessibility of Cys6.47 to MTSEA resulted from a rotation and/or tilting of TM6 associated with receptor activation. Although a substantial backbone movement of TM6 around the Pro-kink might contribute to such a conformational rearrangement, it is also possible that a local change in the relative orientations of Cys6.47 and Trp6.48 may contribute to the difference in the accessibility of Cys6.47 in the inactive and active states. In the simulations we noted an interaction between the side chain of Cys6.47 in t and that of Trp6.48 in g+ (Fig. 3B). In the putative inactive state, this interaction may impact on the dielectric environment of Cys6.47, making it more hydrophobic and likely decreasing the ionization and therefore the reactivity of the thiol. Furthermore, the bulky Trp6.48 side chain may also sterically block MTSEA from accessing Cys6.47. In the putative active state, when Trp6.48 is in the t position, the Trp side chain would be much farther from Cys6.47, and therefore Cys6.47 would be more reactive with MTSEA because of the removal of the factors described above (Fig. 3B).

In considering ways to test this hypothesis, we noted that a Cys residue at position 6.52 would be able to have a similar stabilizing interaction with Trp6.48 in the t conformation (Fig. 3C). Thus, the F2906.52C mutant would have an activation-dependent MTSEA accessibility phenotype opposite to that of WT Cys6.47. That is, in the active state, Trp6.48 in t would be expected to interact with Cys6.52, thereby decreasing its reactivity with MTSEA. Thus, we predicted that F2906.52C would react with MTSEA more rapidly in the WT background than in a CAM background. To test this prediction, we made the mutants F2906.52C in WT and F2906.52C in a well characterized CAM background that contains several mutations at the cytoplasmic end of TM6 (31). The binding affinity of these mutants for [3H]CGP12177 was significantly lower than that of WT receptor (5.8 ± 0.19 nM, n = 4, and 1.4 ± 0.35 nM, n = 3, for F2906.52C in WT and F2906.52C in CAM, respectively). This is consistent with the known role of Phe6.52 in ligand binding (reviewed in Ref. 1). Consistent with the prediction stated above, we found that the rate of reaction of MTSEA with F2906.52C in WT (261 ± 54 M-1 s-1, n = 5) was 5-fold faster than the rate of reaction with F2906.52C in CAM (48 ± 6 M-1 s-1, n = 4) (Fig. 4).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Rate of reaction of F6.52C in the WT background (open circle) and F6.52C in a CAM background (filled circle) with MTSEA. Specific binding was assayed as described under "Experimental Procedures" after a 2-min incubation with the indicated concentration of MTSEA. The mean ± S.E. are shown (n = 4 for WT-F2906.52C; n = 5 for CAM-C2856.47S/F2906.52C).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interactions at the cytoplasmic ends of TM3 and TM6 constrain the relative mobility of these segments in the inactive state of the beta 2AR and related rhodopsin-like receptors (14). Upon release of this "ionic lock" the mobility of TM6 and its position relative to TM3 may be modulated by the configuration of its Pro-kink. If, as we hypothesized, the rotamer position of 6.47 modulates the TM6 Pro-kink, then because the beta -branched Thr does not populate the t rotamer, C2856.47T should favor conformations of the receptor driven by the g+ rotamer, and destabilize those conformations driven by the t rotamer. Because Ser can exist in the t rotamer with a roughly similar frequency as Cys, C2856.47S would be expected to resemble WT receptor in its activation properties.

We found that C2856.47T had multiple properties of a CAM: it had a higher basal level of cAMP accumulation, it had a higher basal level of cAMP in the presence of forskolin, it had a lower EC50 for agonist stimulation of adenylyl cyclase, basal and forskolin-stimulated basal activity was reduced substantially by the inverse agonist timolol, and it had higher affinity for agonist in competition binding studies. Therefore, C2856.47T has the classical characteristics of a CAM, in which a greater fraction of receptor is present in the active state (31, 33). In contrast, C2856.47S had properties similar to that of WT.

Conformational Memories revealed that the rotamer conformations at positions 6.47, 6.48, and 6.52 around Pro6.50 are correlated. A change of 6.48 from g+ (its conformation in the rhodopsin inactive state structure), to t, must be accompanied by a corresponding change of 6.52 to t to avoid steric clash (Fig. 3A). On the other hand, a change of Phe6.52 from t to g+ must be accompanied by a corresponding change of 6.48 to g+ to avoid the same steric clash. Thus in the beta 2AR and related rhodopsin-like receptors these two residues may act in concert as part of a rotamer toggle switch that transduces agonist binding into an altered conformation of TM6 (17). The aromatic stacking interactions between Trp6.48 and Phe6.52 may stabilize the g+/g+ and t/t rotamer configurations. These favorable interactions between 6.48 and 6.52 are facilitated by the presence of the Pro-kink, which brings these two residues closer to each other, altering the relationship between these two side chains from what would be much less favorable interactions in a standard alpha -helix (data not shown).

We also found that the rotamer conformation of 6.47 was significantly correlated with the rotamer of 6.48, making 6.47 a critical part of the rotamer toggle switch. Specifically, 6.47 in g+ was associated with 6.48 in t, and 6.47 in t was associated with 6.48 in g+ (Table III). We propose that the impact of mutation of 6.47 to Thr on activation results from both altered H-bonding as well as modulation by the 6.47 side chain of the rotamer toggle switch. Thus, we propose that Cys6.47g+/Trp6.48t/Phe6.52t represents the active state and that Cys6.47t/Trp6.48g+/Phe6.52g+ represents the inactive state. With Trp6.48 in t in the active state, Phe6.52 must also be in t to avoid steric clash. In contrast, as discussed above, with Trp6.48 in g+ in the inactive state, although there is an increased propensity for 6.52 to be in g+, 6.52 may also exist in t, suggesting the possibility of a diversity of inactive states, with the rotamer positions of 6.47 and 6.48 being more critical to its phenotype.

This hypothesis is consistent with a number of experimental results in rhodopsin. Movement of the side chain of Trp6.48 from g+ to t upon activation is consistent with the inference from UV absorption spectrometry in rhodopsin that the indole side chain of Trp-2656.48 changes orientation during the inactive to active conformational transition (34) as well as with data suggesting that a single Trp tilts toward the membrane during activation (35).

Although 6.52 is an alanine in rhodopsin, in the inactive rhodopsin structure the beta -ionone ring and carbon chain of retinal interact with 6.48 in g+ in a configuration very similar to that of the interaction of 6.48 in g+ with Phe6.52 in g+ in the beta 2AR (Fig. 5). Photoisomerization of retinal from cis to trans moves the beta -ionone ring toward TM4 (36) and thus away from Trp6.48, whose enhanced freedom and subsequent rearrangement is involved in the activation mechanism of rhodopsin. The exquisite lack of constitutive activity of rhodopsin may result from the inability of 6.48 to move to the t rotamer when constrained by bound 11-cis-retinal. For GPCRs, such as the beta 2AR, which are activated by diffusible ligands, a ligand that stabilizes Trp6.48 in the g+ conformation would, therefore, behave as an inverse agonist. One such mechanism of inverse agonism may involve forcing or stabilizing Phe6.52 into the g+ rotamer conformation, which would in turn force Trp6.48 into the g+ conformation, and thereby promote the inactive state. Conversely, an agonist that stabilizes Phe6.52 in the t rotamer conformation would free Trp6.48 to adopt the t conformation, and thereby promote the active state.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 5.   Three-dimensional representation of the similar orientations of 11-cis-retinal/Trp6.48 in rhodopsin (panel A) and Phe6.52/Trp6.48 in beta 2AR (panel B). The chi 1 of Phe6.52 and Trp6.48 are in g+, representing the putative inactive state.

FTIR difference spectroscopy has been used to study the role of cysteine residues in the photoactivation of rhodopsin (37). At least one cysteine sulfhydryl was inferred to be structurally active during rhodopsin photoactivation and to form a stronger hydrogen bond in the activated state. The transmembrane cysteines proposed as candidates are Cys-1674.56, Cys-2225.57, and Cys-2646.47. Movement of Cys6.47 into the g+ rotamer and the associated formation of a strong H-bond with the i-4 carbonyl could be responsible for the spectroscopic observations. In the high-resolution structure of rhodopsin, which represents the inactive state of the receptor (38), the chi 1 of 6.48 is in g+ and the chi 1 of Cys-2646.47 is in a nonstandard rotamer position between g+ and t. The modification of Cys-2646.47 by mercury may have affected its rotamer position. It is also possible that the Cys6.47 side chain may be dynamic, with its coordinates representing the average of its g+ and t rotameric conformations.

Based on the proximity of the side chain of Cys6.47 in t and Trp6.48 in g+ in the beta 2AR simulations, we propose the existence of an interaction between Sgamma of Cys6.47 and the Nepsilon of Trp6.48 (Fig. 3B). This configuration is consistent with the favored orientation of interaction between Cys and Trp in the Residue Contact Atlas (39). The sulfur-aromatic interaction has been characterized as an intermediate interaction between a purely van der Waals interaction and a H-bond (40). In the inactive state of rhodopsin, the side chain of Trp-2656.48 forms a H-bond with another residue (34). In the bovine rhodopsin structure (15), which represents the inactive state of receptor, Cys-2646.47 appears to be the only residue that could form a H-bond-like interaction with the indole side chain of Trp-2656.48. Receptor activation alters tertiary interactions and weakens this H-bond (34). We propose that the interaction between Cys6.47t and Trp6.48g+ in the inactive state accounts for the H-bond feature of Trp-2656.48 that is lost during the activation process.

In our simulations of the beta 2AR, Cys6.47 in t is positioned at an appropriate distance to H-bond to its own backbone carbonyl, i-3 from Pro6.50. H-bonding of the Cys6.47 side chain to its own carbonyl may contribute to the altered psi  angles at 6.47 and 6.48, thereby altering the Pro-kink conformation (Table IV, Fig. 3A) and repositioning the cytoplasmic end of TM6 away from TM3 upon activation. Therefore, Cys6.47, through the interaction of its Sgamma with the indole Nepsilon of Trp6.48 and the H-bond of its side chain to its own carbonyl, may link the conformation of the aromatic cluster with the conformation of the Pro-kink, thereby playing a critical role in the mechanism of receptor activation.

This local network of interactions may underlie the observed correlations between the rotamer conformations of Cys6.47 and Trp6.48. The conformational changes associated with receptor activation must involve a change in interhelical interactions. Interestingly, in the high-resolution structure of bovine rhodopsin, there is a water molecule in the cavity surrounded by Cys6.47, Tyr6.51, Pro6.50, Pro7.38, Phe7.41, and Ala7.42 (38). Okada et al. (38) have hypothesized that electrostatic interactions between TM6 and TM7 through this bound water may stabilize the inactive state, and it is further possible that alterations of these interactions may facilitate the movements associated with activation.

The activation process of rhodopsin has also been found to produce bulk dielectric changes surrounding Trp (34). The proximity of the bulky aromatic side chain of Trp might substantially decrease the accessibility of Cys6.47 in the inactive state, both by decreasing the local dielectric and decreasing the ionization of the sulfhydryl as well as through direct steric block. This is consistent with the observation from our laboratory that Cys6.47 is unreactive with MTSEA in the inactive state (6). In the proposed active state, Cys6.47 and Trp6.48 are substantially further apart, consistent with the observed reactivity of Cys6.47 with MTSEA in the CAM background (6, 7, 14). Based on our simulations and our clustering of the simulated structures into what we inferred to be inactive and active configurations, we hypothesized that in the active state, with 6.48 in the t rotamer, a cysteine substituted for 6.52 might be shielded from reaction with MTSEA, much like Cys6.47 is in the inactive state. We carried out this experiment and found that F2906.52C was ~5-fold less reactive in the CAM background than in the WT background (Figs. 3C and 4), consistent with our predictions. This provides experimental support for the proposed inactive and active configurations and for the existence of a rotamer toggle switch. Thus, with Trp6.48 in the inactive state (g+), Cys6.47 is less accessible and with 6.48 in the active state (t) Cys6.52 is less accessible. In addition, these data are significant because they demonstrate for the first time that in a CAM particular positions are less reactive with MTSEA, thereby arguing against a simple model in which the CAM is simply a less stable, more dynamic molecule.

It is important to note that our simulations are performed with an isolated TM6 out of the context of the helical bundle and lipid. It is clear that studying a helix in isolation ignores known constraining interactions with other TMs, and is clearly inadequate to predict the global configuration of TM6. For this reason, we think it wise not to overinterpret the exact Pro-kink parameters generated by the simulations, and rather to simply note the differences between the two sets of rotamer combinations. Nonetheless, based on the consistency of the results with our experimental findings and the literature, it appears that the methodology can identify local conformations and correlations based on steric clashes and/or local intrahelical interactions, and mutations like those presented here can be designed to test the validity of these hypotheses. In summary, both our experimental and computational results are consistent with the hypothesis that coordinated rotamer changes of 6.47, 6.48, and 6.52 appear to be associated with receptor activation. This rotamer toggle switch may impact the alpha -helix backbone and may modulate the movement of TM6 about the Pro-kink during receptor activation. Because in rhodopsin-like receptors Cys6.47, Trp6.48, and Pro6.50 are highly conserved and 6.52 is conserved as a bulky residue (except in rhodopsin as discussed above), it is likely that the rotamer toggle switch and its modulation of the TM6 Pro-kink are generally involved in GPCR activation.

    ACKNOWLEDGEMENTS

We thank Hanne Hastrup for constructing mutant receptors used in this study as well as for preliminary experiments. We thank Qiang Wang for help with preliminary simulations. We thank Sergio Hassan, Arthur Karlin, Ernest Mehler, Judy Norris, Patricia Reggio, and Harel Weinstein for helpful discussion.

    FOOTNOTES

* This work was supported by National Institute of Mental Health Grants MH57324 and MH54137, grants from the G. Harold & Leila Y. Mathers Charitable Trust, and the Lebovitz Trust (to J. A. J.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Both authors contributed equally to this work.

¶¶ To whom correspondence should be addressed. Tel.: 212-305-7308; Fax: 212-305-5594; E-mail: jaj2@columbia.edu.

Published, JBC Papers in Press, August 6, 2002, DOI 10.1074/jbc.M206801200

2 Although the lack of effect of timolol on the level of basal activity in WT and C2856.47S was not surprising given their lack of substantial constitutive activity (see Ref. 14), it is somewhat surprising that the basal activity in the presence of timolol was higher in WT than in C2856.47S or C2856.47T. This might conceivably relate in part to the 2-fold higher expression level of WT after EEDQ treatment and/or to differences in cAMP levels in the different stable pools that were independent of beta 2 receptor expression.

    ABBREVIATIONS

The abbreviations used are: GPCR, G-protein-coupled receptors; TM, transmembrane; beta 2AR, beta 2 adrenergic receptor; CAM, constitutively active mutants; EEDQ, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; WT, wild type; H-bond, hydrogen bond; MTSEA, methanethiosulfonate ethylammonium.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Shi, L., and Javitch, J. A. (2002) Annu. Rev. Pharmacol. Toxicol. 42, 437-467[CrossRef][Medline] [Order article via Infotrieve]
2. Gether, U. (2000) Endocr. Rev. 21, 90-113[Abstract/Free Full Text]
3. Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., and Khorana, H. G. (1996) Science 274, 768-770[Abstract/Free Full Text]
4. Sheikh, S. P., Zvyaga, T. A., Lichtarge, O., Sakmar, T. P., and Bourne, H. R. (1996) Nature 383, 347-350[CrossRef][Medline] [Order article via Infotrieve]
5. Gether, U., Lin, S., Ghanouni, P., Ballesteros, J. A., Weinstein, H., and Kobilka, B. K. (1997) EMBO J. 16, 6737-6747[CrossRef][Medline] [Order article via Infotrieve]
6. Javitch, J. A., Fu, D., Liapakis, G., and Chen, J. (1997) J. Biol. Chem. 272, 18546-18549[Abstract/Free Full Text]
7. Rasmussen, S. G., Jensen, A. D., Liapakis, G., Ghanouni, P., Javitch, J. A., and Gether, U. (1999) Mol. Pharmacol. 56, 175-184[Abstract/Free Full Text]
8. Jensen, A. D., Guarnieri, F., Rasmussen, S. G., Asmar, F., Ballesteros, J. A., and Gether, U. (2001) J. Biol. Chem. 276, 9279-9290[Abstract/Free Full Text]
9. Arnis, S., Fahmy, K., Hofmann, K. P., and Sakmar, T. P. (1994) J. Biol. Chem. 269, 23879-23881[Abstract/Free Full Text]
10. Scheer, A., Fanelli, F., Costa, T., De, Benedetti, P. G., and Cotecchia, S. (1996) EMBO J. 15, 3566-3578[Medline] [Order article via Infotrieve]
11. Cohen, G. B., Yang, T., Robinson, P. R., and Oprian, D. D. (1993) Biochemistry 32, 6111-6115[CrossRef][Medline] [Order article via Infotrieve]
12. Alewijnse, A. E., Timmerman, H., Jacobs, E. H., Smit, M. J., Roovers, E., Cotecchia, S., and Leurs, R. (2000) Mol. Pharmacol. 57, 890-898[Abstract/Free Full Text]
13. Sheikh, S. P., Vilardarga, J. P., Baranski, T. J., Lichtarge, O., Iiri, T., Meng, E. C., Nissenson, R. A., and Bourne, H. R. (1999) J. Biol. Chem. 274, 17033-17041[Abstract/Free Full Text]
14. Ballesteros, J. A., Jensen, A. D., Liapakis, G., Rasmussen, S. G., Shi, L., Gether, U., and Javitch, J. A. (2001) J. Biol. Chem. 276, 29171-29177[Abstract/Free Full Text]
15. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le, Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Science 289, 739-745[Abstract/Free Full Text]
16. Sansom, M. S., and Weinstein, H. (2000) Trends Pharmacol. Sci. 21, 445-451[CrossRef][Medline] [Order article via Infotrieve]
17. Visiers, I., Ballesteros, J. A., and Weinstein, H. (2002) Methods Enzymol. 343, 329-371[Medline] [Order article via Infotrieve]
18. Ballesteros, J. A., Deupi, X., Olivella, M., Haaksma, E. E., and Pardo, L. (2000) Biophys. J. 79, 2754-2760[Abstract/Free Full Text]
19. Gray, T. M., and Matthews, B. W. (1984) J. Mol. Biol. 175, 75-81[CrossRef][Medline] [Order article via Infotrieve]
20. McGregor, M. J., Islam, S. A., and Sternberg, M. J. (1987) J. Mol. Biol. 198, 295-310[CrossRef][Medline] [Order article via Infotrieve]
21. Ballesteros, J., and Weinstein, H. (1995) Methods Neurosci. 25, 366-428
22. Liapakis, G., Ballesteros, J. A., Papachristou, S., Chan, W. C., Chen, X., and Javitch, J. A. (2000) J. Biol. Chem. 275, 37779-37788[Abstract/Free Full Text]
23. Staehelin, M., Simons, P., Jaeggi, K., and Wigger, N. (1983) J. Biol. Chem. 258, 3496-3502[Abstract/Free Full Text]
24. Jayasinghe, S., Hristova, K., and White, S. H. (2001) Protein Sci. 10, 455-458[Abstract/Free Full Text]
25. Word, J. M., Lovell, S. C., LaBean, T. H., Taylor, H. C., Zalis, M. E., Presley, B. K., Richardson, J. S., and Richardson, D. C. (1999) J. Mol. Biol. 285, 1711-1733[CrossRef][Medline] [Order article via Infotrieve]
26. Guarnieri, F., and Wilson, S. R. (1995) J. Comp. Chem. 16, 648-653[CrossRef]
27. Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., and Karplus, M. (1983) J. Comp. Chem. 4, 187-217[CrossRef]
28. Visiers, I., Braunheim, B. B., and Weinstein, H. (2000) Protein Eng. 13, 603-606[Abstract/Free Full Text]
29. Stapley, B. J., and Doig, A. J. (1997) J. Mol. Biol. 272, 456-464[CrossRef][Medline] [Order article via Infotrieve]
30. Ballesteros, J. A., and Weinstein, H. (1992) Biophys. J. 62, 107-109[Abstract/Free Full Text]
31. Samama, P., Cotecchia, S., Costa, T., and Lefkowitz, R. J. (1993) J. Biol. Chem. 268, 4625-4636[Abstract/Free Full Text]
32. Lovell, S. C., Word, J. M., Richardson, J. S., and Richardson, D. C. (2000) Proteins 40, 389-408[CrossRef][Medline] [Order article via Infotrieve]